Email mdcmy@nus.edu.sg

Dr Mo Yin is the Deputy director of ADVANCE-ID clinical trial network, and an Infectious Diseases physician at the National University Hospital in Singapore. She is the lead investigator for the REGARD-VAP trial (Reducing Antibiotic Treatment Duration for Ventilator Associated Pneumonia) and the ACORN-HAI study (A Clinically-Oriented Antimicrobial Resistance Surveillance Network for Healthcare Associated Infections). She has designed and conducted large multinational clinical trials which focus on pragmatic solutions for antibiotic resistant bacterial infections. She is driven by the ideal of using quality clinical research to improve patient outcomes and propel global policies. She has received numerous awards for her achievements in clinical care, research and teaching. Dr Mo Yin obtained her MBBS from the National University of Singapore and DPhil from University of Oxford.

• National University Hospital, Singapore, Division of Infectious Diseases, University Medicine Cluster – Consultant (2019 – Now)
• National University of Singapore, Department of Medicine – Adjunct Assistant Professor (2025 – Now)
• ADVANCE-ID network, Saw Swee Hock School of Public Health, National University of Singapore – Deputy director (2022 – Now)
• Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand – Honorary research fellow (2022 – Now)
• Oxford Centre for Global Health Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom – Honorary visiting research fellow (2022 – Now)

• Epidemiology, biostatistics, global health, infectious disease, qualitative research, modelling

• Epidemiology biostatistics global health infectious disease qualitative research modelling

• DPhil in Clinical Medicine, University of Oxford, 2022
• Master of Clinical Investigation, National University of Singapore, 2017
• American Board of Internal Medicine Certification, American Board of Internal Medicine, 2013
• Master of Medicine, National University of Singapore, 2013
• Membership of the Royal Colleges of Physicians (Gordon A Ransome Medal and Seah Cheng Siang Medal), Federation of Royal Colleges of Physicians of the United Kingdom, 2013
• Bachelor of Medicine & Bachelor of Surgery, National University of Singapore, 2011
• Singapore-Cambridge General Certificate of Education Advanced Level, Raffles Junior College, 2006

• Asia Pacific Societies of Clinical Microbiology and Infections Institut Merieux Young Investigator Award

• Consultant, Infectious diseases, National University Hospital Singapore (2019 – present)
• Adjunct Assistant Professor, National University of Singapore (2017 – present)
• Senior lecturer, National University of Singapore (2017 – 2025)
• Associate consultant, Infectious diseases, National University Hospital, Singapore (2017 – 2019)
• Senior resident, Infectious diseases, National University Hospital, Singapore (2014 – 2017)
• Resident, Internal medicine, National University Hospital, Singapore (2011 – 2014)

• Deputy director, ADVANCE-ID network, National University Hospital (2020 – present)
• Executive committee member, Singapore Clinical Research Network (2024 – present)
• Senior chief resident, National University Hospital (2014 – 2017)
• Doctors-in-training committe, Singapore Medical Association (2016 – 2017)
• Chairperson of resident research committee, National University Hospital (2015 – 2016)
• Singapore Chief Residency Programme, Ministry of Health (2015 – 2016)
• Chairperson of Junior Unit Against Inefficiencies and Patient Safety, National University Hospital (2014 – 2016)
• Chief resident, National University Hospital (2012 – 2014)

• Consultations for World Health Organisation
  • West African Ebola epidemic 2015
  • COVID-19 pandemic 2020 – 2023
  • Expert Consultation on Strengthening Clinical Trials in the Western Pacific for the WHO 2024 – 2025
  • Capacity training materials for clinical trials to support the WHO Clinical Trials guideline
  • Clinical Trials Unit Maturity Framework – Development Writing Group
• Advisory Group on the R&D of antibacterial treatments: 2025 pipeline report
• Peer review for scientific journals and international conferences
• Pandemic preparedness workshop for the Ministry of Foreign Affairs 2016
• COVID-19 pandemic 2020 – 2023
• International advisory board for SNIP-AFRICA 2024
• Evidence for action (e4a) dialogue on antimicrobial resistance 2024
• International expert panel for a Just Transitions framework for equitable and sustainable mitigation of antimicrobial resistance 2023 – 2025
• Partner for Good Clinical Trial Collaborative 2024
• Regulatory Science of Antimicrobial Agents Workshop 2024

• Yin Mo, Cherry Lim, James A Watson, Nicholas J White, Ben S Cooper. Non-adherence in non-inferiority trials: pitfalls and recommendations. BMJ. 2020;370:m2692. Published 2020 Jul 10. doi:10.1136/bmj.m2692.
• Mo Y, Booraphun S, Li AY, Domthong P, Kayastha G, Lau YH, Chetchotisakd P, Limmathurotsakul D, Tambyah PA, Cooper BS; REGARD-VAP investigators. Individualised, short-course antibiotic treatment versus usual long-course treatment for ventilator-associated pneumonia (REGARD-VAP): a multicentre, individually randomised, open-label, non-inferiority trial. Lancet Respir Med. 2024 Jan 22:S2213-2600(23)00418-6. doi: 10.1016/S2213-2600(23)00418-6.
• Sheila RV, Clare IRC, Kym W, Syed MA, Caesar A, Deepshikha B, Susan JB, Sander C, Hindrik RVD, Ashish G, René G, Steve H, Calvin H, Pablo I, Marina J, Claas K, Taciano LM, Sassy M, Edna NM, Christopher P, Nenene Q, Yin M, Phaik YC, Sonia L. A just transition for antimicrobial resistance: planning for an equitable and sustainable future with antimicrobial resistance. Lancet. 2024 Jun 29;403(10446):2766-2767. doi: 10.1016/S0140-6736(23)01687-2.
• Yin M, Tambyah PA, Perencevich EN. Infection, Antibiotics, and Patient Outcomes in the Intensive Care Unit. JAMA. 2020 Apr;323(15):1451-1452. doi: 10.1001/jama.2020.2241.
• Harris PN, Tambyah PA, Lye DC, Mo Y; MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN). Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial. JAMA. 2018 Sep 11;320(10):984-994. doi: 10.1001/jama.2018.12163.
• Cooper BS, Evans S, Jafari Y, Pham TM, Mo Y, Lim C, Pritchard MG, People D, Hall V, Stimson J, Eyre DW, Read JM, Donnelly CA, Horby P, Watson C, Funk S, Robotham JV, Knight GM. The burden and dynamics of hospital-acquired SARS-CoV-2 in England. Nature. 2023 Oct 18;623:132-138. doi: 10.1038/s41586-023-06634-z.
• Mo Y, Lim C, Watson JA, White NJ, Cooper BS. Non-adherence in non-inferiority trials: pitfalls and recommendations. BMJ. 2020 Jul;370:m2215. doi: 10.1136/bmj.m2215
• Chhabra S, Mo Y. Concerning the use of aminoglycosides in ventilator-associated pneumonia – Authors’ reply. Lancet Respir Med. 2024 Aug;12(8):e46. doi: 10.1016/S2213-2600(24)00206-6. PMID: 39089762.
• Mo Y, Booraphun S, Li AY, Domthong P, Kayastha G, Lau YH, Chetchotisakd P, Limmathurotsakul D, Tambyah PA, Cooper BS; REGARD-VAP investigators. Individualised, short-course antibiotic treatment versus usual long-course treatment for ventilator-associated pneumonia (REGARD-VAP): a multicentre, individually randomised, open-label, non-inferiority trial. Lancet Respiratory Medicine. 2024 May;12(5):399-408. doi: 10.1016/S2213-2600(23)00418-6.
• Harris PN, Wang AD, Yin M, Lee CK, Archuleta S. Atypical hand, foot, and mouth disease: eczema coxsackium can also occur in adults. The Lancet Infectious Diseases. 2014 Nov;14(11):1043. doi: 10.1016/S1473-3099(14)70976-4.
• Cai Y, Booraphun S, Li AY, Kayastha G, Tambyah PA, Cooper BS, Graves N, Mo Y. Cost-effectiveness of a short-course antibiotic treatment strategy for the treatment of ventilator-associated pneumonia: an economic analysis of the REGARD-VAP trial. Lancet Global Health. 2024 Dec;12(12):e2059-e2067. doi: 10.1016/S2214-109X(24)00327-9. PMID: 39510104; PMCID: PMC11579304.
• Mo Y, Hernandez-Koutoucheva A, Musicha P, Bertrand D, Lye D, Ng O, et al. Duration of Carbapenemase-Producing Enterobacteriaceae Carriage in Hospital Patients. Emerg Infect Dis. 2020 Sep;26(9):2182-2185. doi: 10.3201/eid2609.190592
• Mo Y, Oonsivilai M, Lim C, Niehus R, Cooper BS. Implications of reducing antibiotic treatment duration for antimicrobial resistance in hospital settings: A modelling study and meta-analysis. PLoS Med. 2023 Jun 15;20(6):e1004013. doi: 10.1371/journal.pmed.1004013.
• Mo Y, Eyre DW, Lumley SF, Walker TM, Shaw RH, O’Donnell D, Butcher L, Jeffery K, Donnelly CA; Oxford COVID infection review team, Cooper BS. Transmission of community- and hospital-acquired SARS-CoV-2 in hospital settings in the UK: A cohort study. PLoS Med. 2021 Oct 12;18(10):e1003816. doi: 10.1371/journal.pmed.1003816.
• Mo Y. Rapid Diagnostics for Antibiotic Resistance: Urgent Need for Strong Clinical Evidence. Clinical Infectious Diseases. 2022 Dec 19;75(12):2076-2078. doi: 10.1093/cid/ciac358.

• Shortened Antibiotic Treatment for Ventilator-associated Pneumonia in ICU Patients just as Effective as Standard Course, MediCine newsletter, 2024
• Trial Backs Short Course of Antibiotics for Ventilator-Associated Pneumonia — Individualised treatment noninferior versus usual long-course treatment in the ICU, Medpage, 2024
• 缩短肺炎重症抗生素疗程不减疗效, Lianhezaobao, 2024
• Collaborating for success – an interview with Dr. Mo Yin of ADVANCE-ID, Good Clinical Trial Collaborative, 2023
• How collaboration can help tackle drug-resistant infections, Wellcome Trust Linkedin, 2023
• Antimicrobial resistance could kill more people than cancer by 2050, experts say, The Straits Times, 2023
• S’pore research team gets $10m grant to fight drug-resistant superbugs, The Straits Times, 2023